Literature DB >> 31344431

The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?

Yalda Hekmatshoar1, Yalda Rahbar Saadat2, Seyed Mahdi Hosseiniyan Khatibi3, Tulin Ozkan1, Fatemeh Zununi Vahed4, Ziba Nariman-Saleh-Fam5, Bahram Pourghassem Gargari6, Asuman Sunguroglu1, Sepideh Zununi Vahed7.   

Abstract

Cancer is a globally challenging health problem threatening mankind. Despite therapeutic advances in dealing with this malignancy, heterogeneous response and resistance to chemotherapeutic agents remain the hallmarks of cancer therapy. On the other hand, the involvement of the microbiota in affecting human health is well defined. An ever-growing body of evidence implicates the potential link between the microbiome and the efficacy of cancer therapies. Gut microbiota can modulate the metabolism of drugs in a number of ways. The presence of bacteria within the tumor environment can also impact the responses to cancer therapies; changing the chemical structure of chemotherapeutic drugs, affecting their activity, and local concentration. However, the underlying mechanisms by which gut and tumor microbial communities affect the response to cancer therapy are poorly understood and deciphering these mechanisms is of paramount importance. This review provides an overview of how gut and tumor microbiota might affect the efficacy of chemotherapy, radiotherapy, and immunotherapy and alleviate the adverse side effects of these therapies for the development of personalized and effective anticancer therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Gut microbiota; Immunotherapy; Microbiome; Radiotherapy; Tumor microbiota

Mesh:

Substances:

Year:  2019        PMID: 31344431     DOI: 10.1016/j.lfs.2019.116680

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

Authors:  Romain Villéger; Amélie Lopès; Guillaume Carrier; Julie Veziant; Elisabeth Billard; Nicolas Barnich; Johan Gagnière; Emilie Vazeille; Mathilde Bonnet
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

2.  Dietary Recombinant Phycoerythrin Modulates the Gut Microbiota of H22 Tumor-Bearing Mice.

Authors:  Hongtao Qi; Ying Liu; Xin Qi; Hui Liang; Huaxin Chen; Peng Jiang; Dongfeng Wang
Journal:  Mar Drugs       Date:  2019-11-26       Impact factor: 5.118

Review 3.  Radiotherapy and the gut microbiome: facts and fiction.

Authors:  Jing Liu; Chao Liu; Jinbo Yue
Journal:  Radiat Oncol       Date:  2021-01-13       Impact factor: 3.481

Review 4.  The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review.

Authors:  Byeongsang Oh; Thomas Eade; Gillian Lamoury; Susan Carroll; Marita Morgia; Andrew Kneebone; George Hruby; Mark Stevens; Frances Boyle; Stephen Clarke; Brian Corless; Mark Molloy; David Rosenthal; Michael Back
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

5.  Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.

Authors:  Justin Chau; Meeta Yadav; Ben Liu; Muhammad Furqan; Qun Dai; Shailesh Shahi; Arnav Gupta; Keri Nace Mercer; Evan Eastman; Taher Abu Hejleh; Carlos Chan; George J Weiner; Catherine Cherwin; Sonny T M Lee; Cuncong Zhong; Ashutosh Mangalam; Jun Zhang
Journal:  BMC Cancer       Date:  2021-07-13       Impact factor: 4.430

Review 6.  Diet, Microbiome, and Cancer Immunotherapy-A Comprehensive Review.

Authors:  Michał Szczyrek; Paulina Bitkowska; Patryk Chunowski; Paulina Czuchryta; Paweł Krawczyk; Janusz Milanowski
Journal:  Nutrients       Date:  2021-06-28       Impact factor: 5.717

Review 7.  From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Authors:  Giovanni Vitale; Alessandra Dicitore; Luigi Barrea; Emilia Sbardella; Paola Razzore; Severo Campione; Antongiulio Faggiano; Annamaria Colao; Manuela Albertelli; Barbara Altieri; Filomena Bottiglieri; Federica De Cicco; Sergio Di Molfetta; Giuseppe Fanciulli; Tiziana Feola; Diego Ferone; Francesco Ferraù; Marco Gallo; Elisa Giannetta; Federica Grillo; Erika Grossrubatscher; Elia Guadagno; Valentina Guarnotta; Andrea M Isidori; Andrea Lania; Andrea Lenzi; Fabio Lo Calzo; Pasquale Malandrino; Erika Messina; Roberta Modica; Giovanna Muscogiuri; Luca Pes; Genoveffa Pizza; Riccardo Pofi; Giulia Puliani; Carmen Rainone; Laura Rizza; Manila Rubino; Rosa Maria Ruggieri; Franz Sesti; Mary Anna Venneri; Maria Chiara Zatelli
Journal:  Rev Endocr Metab Disord       Date:  2020-09-15       Impact factor: 9.306

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.